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rovoked Coronary Spasm and
cute Coronary Syndromes*
arl J. Pepine, MD, MACC
ainesville, Florida
lthough coronary artery spasm (CAS) has been linked
ith acute coronary syndromes (ACS) and vulnerable
laque (1), thrombosis (2), percutaneous coronary interven-
ion (PCI), and stenting (3–7), very limited attention is
iven to CAS in the current era. This may be related to
ssumptions that the frequency of CAS is decreasing and if
resent it will be eliminated with calcium antagonist (8) or
itrate use. However, concerns about adverse outcomes in
ypertensive and angina patients over the past decade have
iminished calcium antagonist use, particularly in ACS.
ong-acting nitrates, once a standard discharge order, are
ot recommended discharge medications in recent ACS
uidelines (9–11). Important to the perception that CAS is
ecreasing is the lack of testing to detect spasm as a possible
echanism for ACS when other causes are not apparent.
xcept for Prinzmetal angina and cocaine use, CAS testing
s either not mentioned (9,10) or is given only a IIb
ecommendation (11) among patients without obstructive
oronary artery disease (CAD) in recent guidelines. There-
ore, among ACS patients the frequency of CAS was
nknown, and it was uncertain whether it was simply a
ediator of ischemia among other factors, a marker pre-
icting adverse outcome, or both.
See pages 518 and 523
This is the setting for 2 provocative reports on coronary
pasm in ACS published in this issue of the Journal. Using
prospective cohort design, Wakabayashi et al. (12) tested
onsecutive Japanese patients for CAS 10 to 20 days after
cute myocardial infarction (MI) treated by PCI. Spasm was
rovoked in about 70% of cases, and almost one-half of
hese had an event (death, ACS, or revascularization) over
ollow-up. Spasm was provoked in the majority of arteries
xamined; occurring in approximately 70% of infarct-related
rteries and about one-half of noninfarct-related arteries.
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.a
From the Division of Cardiovascular Medicine, Department of Medicine, Univer-
ity of Florida College of Medicine, Gainesville, Florida.inding CAS in these latter cases indicates that spasm was
ot related to vascular injury associated with the PCI.
rovoked spasm was an independent predictor of adverse
utcome, and although exploratory, their analysis suggests
hat CAS may be linked with early nonobstructive vulner-
ble plaque as a precursor to recurrent ACS in multiple
rteries rather than only the infarct-related lesion. Ong et al.
13) continued this theme of spasm testing in ACS patients
ithout obstructive lesions. Spasm was provoked in approx-
mately 50% of these marker-positive (electrocardiographic
ECG] and/or biochemical) Caucasian cases. Interestingly,
moking history, long recognized as a risk condition for
pasm (14), was present in only about one-fourth of these
ases and did not differ significantly comparing those with
nd without spasm. This also held true for other factors
reviously linked with CAS, such as female gender and
ypertension.
Although these data, indicating a very high frequency of
ultivessel CAS in ACS patients possibly linked with
dverse outcomes, are very interesting, there are some
imitations. The Wakabayashi et al. (12) study conclusions
ould be stronger if the outcome included only death or
I. These were Japanese patients in whom smoking prev-
lence exceeded 60% and spasm prevalence is higher than in
aucasians (15). Although Ong et al. (13) identified spasm
n one-half of the ACS cases without obstructive CAD, we
o not know whether this finding also portents a high risk
or adverse outcome in Caucasian patients with less smoking
istory versus Japanese patients. Therefore conclusions link-
ng spasm after MI with adverse outcomes require confir-
ation in non-Asian patients. Also the frequency of clas-
ified spasm may vary with the provocation test (agent, route
f administration) and the definition (from total to near-
otal occlusion with or without symptoms, and so on). Both
tudies used intracoronary acetylcholine and an angio-
raphic diagnosis of spasm associated with clinical findings.
akabayashi et al. (12) defined CAS as transient total or
ubtotal occlusion with ECG changes and/or typical chest
ymptoms. Ong et al. (13) defined CAS when quantitative
nalysis confirmed 75% narrowing (compared with the
elaxed state after nitroglycerin) and symptom reproduction.
hese subtle differences in CAS definition would not be
xpected to influence the conclusions in an important
anner.
uestions on the Theme of Spasm
n ACS and Some Future Areas for Development
hat is the prevalence of nonobstructive lesions in ACS
here CAS could play a role in ischemia? Although past
eports suggested nonobstructive CAD in about 25% of
CG and/or biomarker-positive ACS patients (16), our
xperience suggests that the frequency now approximates
0% to 50%. This likely relates to improved biomarker
iagnosis of ACS (17) as well as increased use of
therothrombosis-preventative treatments.
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August 12, 2008:528–30 Editorial Commenthat is the prevalence of CAS in these ACS patients
ithout obstructive lesions? Although ACS patients un-
ergo risk stratification, consideration is not routinely given
o CAS among cases without obstructive lesions. Although
he association between ST-segment elevation and CAS in
atients with chest pain is well documented, it should be
mphasized that most patients with CAS do not have
T-segment elevation when seen in the emergency depart-
ent or office with chest pain (18,19). The important
linical point is that absence of ST-segment elevation
uring chest pain should not exclude CAS. Noninvasive
ests can document ischemia and further quantify risk, but
he reference standard for CAS is visualization during
ngiography in association with symptoms and/or signs of
schemia.
 h y does the frequency of CAS seem to be decreasing?
odification of atherosclerosis risk factors, in particular
igarette smoking, which has been strongly associated with
AS (14), and statin and calcium antagonist use (8) account
or some reduction. But with the increase in diabetes (20),
ypertension, obesity, drug-eluting stent use (4,5,7), and
ethamphetamines or cocaine use (11), it would be unlikely
hat the incidence of spasm is truly declining. It is more
ikely that the decline in testing accounts for the perception
hat spasm has declined. If the high CAS prevalence noted
bove can be reproduced but the frequency of CAS may
ctually be increasing, it remains to be determined whether
rovoked CAS portends high risk for adverse outcomes in a
aucasian ACS population.
s spasm testing of value in the management of ACS
atients? This is the critical question and would require an
dequately powered, randomized study assessing the out-
omes impact of a routine CAS detection and management
trategy in ACS compared with the prevailing strategy of
ery restricted attempts at CAS detection and management.
he vast majority of patients with either spontaneous or
rovoked CAS have coronary atherosclerosis (obstructive or
onobstructive) as do those with ACS, and with over 1.5
illion ACS patients (primary and secondary diagnoses)
21), the population exists to properly address this question.
ome Thoughts on the
echanism(s) of Coronary Spasm
ocus has been on a defect that spontaneously increases
oronary tone, narrowing the lumen to limit flow and result
n ischemia. Although perceived as a disorder of epicardial
rteries, intramyocardial vessels are also likely involved (22).
hile the final pathway is associated with the KATP
hannels in smooth muscle cells, it is likely that processes
xtrinsic to smooth muscle also participate (23,24). These
nclude endothelial cells, where KATP channel opening by
denosine and alpha2-adrenergic receptor stimulation con-
ributes to nitric oxide generation and vasodilation. Endo-
helial dysfunction with loss of KATP channels and attenu-
ted nitric oxide production and/or bioavailability promotesmooth muscle hypercontractility. Another possibility in-
ludes the sympathetic neurons, where opening of presyn-
ptic KATP channels attenuates norepinephrine release en-
ancing smooth muscle relaxation to dilate coronary
rteries. A defect in these channels decreasing the threshold
or norepinephrine release may be associated with spasm.
nother possibility relates to bone marrow-derived cells
ecruited to the vessel wall and their products (25,26).
ndeed, identification of specific mechanisms of CAS and
schemia-related adverse outcomes requires further study in
xperimental models and patients. Considerable species
ariability exists in atherosclerosis models, so mechanisms
or CAS in humans and experimental models might not be
he same. Nevertheless, smooth muscle and extrinsic pro-
esses are likely to be important in CAS pathogenesis, and
nvestigations in this area could yield new therapies for these
CS patients.
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